In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish ...

Precision BioSciences reports early PBGENE-HBV trial data showing safety and antiviral activity in chronic Hepatitis B patients, with more results expected in 2025.

The trial was tailored to evaluate the therapy at multiple ascending dose levels, with three dose administrations per level.

Assays for hepatitis B surface antigen (HBsAg) are the most frequently used tests to detect HBV infection. Vaccination for HBV can produce transiently detectable levels of HBsAg in patients.

Mayo Clinic researchers have discovered a new immunotherapy target, a cryptic antigen, that may be key in helping the immune system fight tumors in ovarian cancer. The study, published in Science ...

Precision BioSciences (NASDAQ:DTIL) added ~6% in the premarket on Wednesday after the gene therapy developer announced ...

Dagger; Approximately five copies = 1 IU. ALT: Alanine aminotransferase; HBeAg: Hepatitis B e antigen; HBV: Hepatitis B virus. IgM anti-HBc Presence with high index value during acute HBV ...

The NHS will automatically test patients for HIV, Hepatitis B and Hepatitis C unless they opt out at almost 90 Accident and Emergency (A&E) units in England, the BBC can reveal. The government is ...

bepirovirsen at a dose of 300 mg per week over 24 weeks resulted in sustained hepatitis B surface antigen (HBsAg) and HBV DNA loss to below the limits of detection in 9% to 10% of participants ...

With several drugs in use that inhibit the hepatitis B virus polymerases (nucleos(t)ide analogues (or NUCs)), some argue that new direct-acting antiviral drugs, and new NUCs in particular ...

Berkshire Hathaway Inc., through its subsidiaries, engages in the insurance, freight rail transportation, and utility businesses worldwide. The company provides property, casualty, life, accident ...